The Hindu Business Line : Dr Reddy’s betting big on ‘myDREEM’ project

At the heart of ‘myDREEM’ is a proactive and seamless IT network which aims to achieve excellence in the execution of projects and all activity that the company takes up

Our Bureau

Hyderabad, July 21

The country’s top pharma company in revenue terms, Dr Reddy’s Laboratories, has put in place a ‘myDREEM’ project that is propelling its growth story.

Across the board, all the initiatives of the company , are being optimised through this project, on which Dr K. Anji Reddy, founder and Chairman, is betting big.

At the heart of ‘myDREEM’ is a proactive and seamless IT network.

This network, manned by dedicated professionals, aims to achieve excellence in the execution of projects and all activity that the company takes up.

To ensure that this project gives utmost results, the management has been quietly making efforts to create various building blocks for sustainable growth.

Dr Reddy’s has taken a leaf from engineering and automobile industries to create a lean manufacturing organisation across all its businesses.

Historic milestone

Giving a detailed account of how Dr Reddy’s Laboratories climbed to the country’s top slot in the pharma and drug sector, with what he described as the crossing of the historic $1.5-billion milestone during fiscal 2006-07, Dr Anji Reddy assured shareholders that with Rs 1,001.3 crore raised through ADR and comfortable debt-equity ratio of 0.59 as on March 31, 2007, Dr Reddy’s is well positioned to scale new heights.

In his Chairman’s letter to shareholders, Dr Reddy said in the last two years, the company achieved solid baseline results, over and above which will come the upside gains from new generics launches, specialty pharmaceuticals, biologics and drug discovery.

Headcount

Referring to having on board about 2,000 international employees and creating global managerial skills, Dr Reddy said during 2006-07, the company added 1,500 people, taking the total employee strength to 9,000, representing 45 nationalities.

In addition to the acquisitions of Betapharm and Roche’s unit in Mexico contributing significantly, Dr Reddy’s is banking on the 7 molecules or New Chemical Entities, of which 5 are in clinical development and two at pre-clinical stage to shore up its prospects in the long term.

More Stories on : Outlook | Pharmaceuticals | Dr. Reddy's Laboratories Ltd

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
RIL hikes petrol, diesel retail prices

Suryachakra enters power supply deal with Tata

ICAI to adopt global standards from 2011

Profit boost for overseas borrowers

Drug companies will continue to face hard times

Dr Reddy’s betting big on ‘myDREEM’ project

LG Electronics turnover rises 20% in first half